BPC-157

What is BPC-157?

BPC-157 (English Body Protective Compound 157) is a synthetic pentadecapeptide composed of 15 amino acids. Its sequence is given in the literature as GEPPPGKPADDAGLV. It derives from a smaller protein fragment that researchers discovered in gastric juice, which is why it is often described as a “gastric peptide”.

Although the public often associates it with regeneration, it must be emphasised: BPC-157 is not an approved medicine. It is a research compound used in laboratory and preclinical models.

What do preclinical studies show?

Most published data come from studies in rodents and cell cultures. In these models, researchers reported accelerated healing after injuries to tendons, ligaments and muscles, and better outcomes in models of gastric ulcers. Possible mechanisms cited include:

• angiogenesis — the formation of new blood vessels, important for supplying tissue with oxygen;
• fibroblast migration — cells that build connective tissue and collagen;
• modulation of nitric oxide and signalling pathways associated with healing;
• stability in an acidic environment, which is one of the reasons for researchers’ interest.

These mechanisms are biologically plausible, but they do not in themselves prove clinical benefit. Results in animals often do not transfer directly to humans.

What do we know about use in humans?

Clinical evidence is modest. To date there are no large, independently replicated randomised trials confirming the efficacy and safety of BPC-157 in humans. This means that claims of “proven” effects are exaggerated, and the frequency and severity of possible adverse effects have not been sufficiently studied.

For researchers it is therefore important to treat the results of preclinical models as a hypothesis, not a conclusion. We have written more about how to read such studies in the overview of BPC-157 research.

Quality, purity and documentation

With peptides, purity is crucial because impurities can influence experimental results and complicate interpretation. The specification declares a purity of ≥ 99 % by HPLC analysis, and identity is described by mass spectrometry. If a batch number is stated on the vial, it can be linked to an analytical report. Without matching numbers, the documentation cannot be attributed to the sample.

What the individual figures mean and how to recognise an inadequate certificate is described in the article How to read a certificate of analysis (COA).

Storage and handling

The lyophilized powder must be stored at −20 °C, protected from light and moisture. Before opening, allow the vial to reach room temperature to prevent condensation. After reconstitution, the solution must be stored at 2–8 °C in accordance with the laboratory protocol. Detailed instructions are in the guide to storage and reconstitution.

Conclusion

BPC-157 is one of the most studied regenerative peptide compounds in the preclinical setting, but it remains a research question, not a medicine. For laboratory use, purity, batch traceability and correct storage matter — not marketing promises.